Phase II study of pyrazofurin in advanced colorectal carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology; D000577:Amides; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000276:immunology; D004064:Digestive System / Q000187:drug effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008214:Lymphocytes / Q000276:immunology; D011379:Prognosis; D011720:Pyrazoles; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D012263:Ribonucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012266:Ribose
D000577:Amides; D000903:Antibiotics, Antineoplastic; D011720:Pyrazoles; D012263:Ribonucleosides; C002997:pyrazofurin; D012266:Ribose